CM
SUPN icon

Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-195,489
Closed -$3.52M – 74
2020
Q1 		$3.52M Sell
195,489
-28,001
-13% -$588K 1.29% 32
2019
Q4 		$5.3M Sell
223,490
-8,540
-4% -$207K 1.35% 33
2019
Q3 		$6.38M Buy
232,030
+41,740
+22% +$1.24M 1.75% 30
2019
Q2 		$6.3M Buy
190,290
+18,420
+11% +$631K 1.74% 30
2019
Q1 		$6.02M Sell
171,870
-102,587
-37% -$3.82M 1.65% 29
2018
Q4 		$9.12M Buy
274,457
+49,225
+22% +$2.12M 2.83% 12
2018
Q3 		$11.3M Buy
225,232
+118,152
+110% +$5.83M 2.9% 10
2018
Q2 		$6.41M Sell
107,080
-32,455
-23% -$1.68M 1.72% 31
2018
Q1 		$6.39M Buy
139,535
+4,715
+3% +$197K 1.72% 29
2017
Q4 		$5.37M Buy
134,820
+23,220
+21% +$918K 1.46% 33
2017
Q3 		$4.46M Sell
111,600
-5,400
-5% -$234K 1.27% 34
2017
Q2 		$5.04M Sell
117,000
-4,660
-4% -$166K 1.51% 33
2017
Q1 		$3.81M Buy
121,660
+220
+0.2% +$5.9K 1.18% 34
2016
Q4 		$3.07M Buy
121,440
+57,645
+90% +$1.29M 1.02% 39
2016
Q3 		$1.58M Buy
63,795
+28,165
+79% +$637K 0.58% 42
2016
Q2 		$726K Buy
+35,630
New +$632K 0.28% 54

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Capital Management's SUPN Position: Q2 2020 in Review

Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2020, closing a stake of 195,489 shares — an estimated $3.52M sold.

Capital Management first reported a position in SUPN in Q2 2016 and held it in 16 quarters. The position peaked at $11.3M in Q3 2018. 218 funds tracked by Wall St. Rank hold SUPN as of Q2 2020.

  • Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Capital Management sold 195,489 Supernus Pharmaceuticals shares in Q2 2020, an estimated $3.52M.
  • Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2016 and held it in 16 quarters.
  • Capital Management's Supernus Pharmaceuticals position peaked at $11.3M in Q3 2018.
  • 218 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2020.

Based on Capital Management's 13F filing for Q2 2020, filed 29 Jul 2020.